Neometals Ltd {ASX: NMT} and Mineral Resources Limited {ASX: MIN} have confirmed the agreement with China’s second largest lithium producer, Jiangxi Ganfeng Lithium Co., is now unconditional.

This is a very significant achievement in a poor commodities market.

Mt Marion Lithium Project Offtake and Equity Investment
Transaction unconditional

Neometals Ltd {ASX: NMT} and Mineral Resources Ltd. {ASX: MIN} (via its
wholly owned subsidiary, Process Minerals International Pty Ltd), refer to their previous
announcements regarding the execution of formal agreements with China’s second largest lithium producer, Jiangxi Ganfeng Lithium Co., Ltd, in respect of Ganfeng’s equity investment in the Mount Marion Lithium Project.

Neometals and MIN are pleased to advise that the transaction is now unconditional.

Financial close is expected to occur within the next 2 weeks.

ENDS
For further information, please contact:
Chris Reed
Managing Director
Neometals Ltd
+61 8 9322 1182
info@neometals.com.au
Bruce Goulds
CFO/Company Secretary
Mineral Resources Limited
+61 8 9329 3600
bruce.goulds@mineralresources.com.au

Media
Richard Glass / Michael Weir
Citadel-MAGNUS
+61 8 6160 4900

The next City Investors Circle evening presentation is scheduled for Thursday 15th October, in the City of London, at 18.00 for 18.30.

The venue and presenting companies will be confirmed within the next few days.

Scorpio Gold {TSX.V: SGN} has released further results from their Brodie Satellite deposit at Mineral Ridge, Nevada, USA.

Highlight is hole MR151658, with 12.55 g/t gold over 3.05 meters.

Comment

Further good results at Brodie,and the 12.55 Grams per ton at over three metres speaks for itself.

Scorpio keep the good news coming but the shareprice fails to respond, even though they are in production and making a modest profit, which finances further exploration.

The limited LOM is the obvious possible reason, but they always manage to replace what they mine each year, so provided that continues it may become less of a drag on the SP moving forwards.

——-

Scorpio Gold Reports Results from 2015 Expansion Drilling at the Brodie Satellite Deposit, Mineral Ridge Project, Nevada.

About Scorpio Gold

Scorpio Gold holds a 70% interest in the producing Mineral Ridge gold mining operation located in Esmeralda County, Nevada with joint venture partner Waterton Global Value L.P. (30%). Mineral Ridge is a conventional open pit mining and heap leach operation. The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages. Scorpio Gold also holds a 100% interest in the advanced exploration-stage Goldwedge property in Manhattan, Nevada, with a fully permitted underground mine and 400 ton per day mill facility. The Goldwedge mill facility has been placed on a care and maintenance basis for the near-term and can be restarted immediately when needed.

Scorpio Gold’s President & CEO, Peter J. Hawley, PGeo,, is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the content of this release.

ON BEHALF OF THE BOARD
SCORPIO GOLD CORPORATION

Peter J. Hawley,
President & CEO

For further information contact:
Peter J. Hawley, CEO
+1 819 825 7618
phawley@scorpiogold.com

Inovio Pharmaceuticals {NASDAQ: INO} have announced yet another grant from DARPA, to the tune of $24 million, for further work on their Ebola DNA based vaccine development.

In a clinical trial the vaccine protected 100% of monkeys, and the next step, a clinical trial, is fully enrolled.

Inovio Receives $24 Million Option Grant from DARPA to Advance Ebola Program Development

Clinical trial fully enrolled; Vaccine protected 100% of monkeys in Ebola virus challenge

PLYMOUTH MEETING, Pa. – Sep 21, 2015 – Inovio Pharmaceuticals, Inc. {NASDAQ: INO} announced today that the U.S. Defense Advanced Research Projects Agency (DARPA) has exercised its option to provide an additional $24 million to support the Inovio-led development of multiple treatment and prevention approaches against Ebola.

The option exercise, part of the $45 million Ebola program grant announced in April when Inovio received an initial $21 million award, was contingent upon Inovio successfully leading the completion of certain pre-clinical and clinical development milestones.

 
DARPA has funded this program to develop a DNA-based vaccine against Ebola, a therapeutic DNA-based monoclonal antibody product (dMAb™) to treat Ebola infection, and a conventional monoclonal antibody to treat Ebola.
In the intervening period from the grant award in April, Inovio and its collaborators have accomplished:

• Full enrollment of 75 volunteers for the phase I clinical study for Inovio’s Ebola vaccine, INO-4212. Interim safety and immune response data is expected to be reported in 4Q 2015.
• Complete protection of vaccinated monkeys from a lethal Ebola virus challenge.
• Significant pre-clinical proof-of-concept demonstrated in animal models for the potential of its dMAb technology including with Ebola dMAb constructs. Screening of different Ebola dMAbs in pre-clinical studies is ongoing. Inovio recently reported the publication of its anti-dengue dMAb demonstrating protection against lethal challenge.

Dr. J. Joseph Kim, President and CEO, said, “Inovio is executing all aspects of the Ebola program as planned. The DARPA program is funding an accelerated R&D program that is simultaneously working on three different counter-measures. Access to the full DARPA funding based on the accomplishment of certain program milestones allows Inovio and its collaborators to carry out all the elements of the proposal as rapidly as possible.”

 
Inovio is leading a world-class collaboration of industry and academic partners in an effort to prevent and treat Ebola including: MedImmune, the global biologics research and development arm of AstraZeneca; GeneOne Life Sciences of Korea (KSE: 011000) and its U.S. manufacturing subsidiary, VGXI, Inc.; the Perelman School of Medicine at the University of Pennsylvania; and researchers at Emory University and Vanderbilt University.

 
DARPA, an agency of the U.S. Department of Defense that creates and supports novel technologies important for national security, has selected Inovio to develop products that if successful can add to the arsenal of rapid response capabilities. Inovio’s Ebola program is initially targeted to treat first responders and Ebola-infected health care workers and patients, but could potentially be widely utilized to stem the spread of an Ebola outbreak.

About the Ebola Virus

The Ebola virus causes periodic outbreaks of a highly contagious and lethal human infectious disease marked by severe hemorrhagic fever, with a mortality rate that ranges between 50 and 90%. The infection typically affects multiple organs in the body and is often accompanied by severe bleeding. The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission.

At present, there are no U.S. FDA-approved pre- or post-exposure interventions available in the event of an outbreak, laboratory accident, or deliberate misuse. The Ebola virus is classified as a Category “A” Priority Pathogen by the U.S. Centers for Disease Control and Prevention. This designation prescribes an accelerated development pathway for FDA approval that determines efficacy based on two different validated animal studies followed by clinical evaluation in phase 1 and phase 2 trials to establish safety and immunogenicity for use in humans.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that is generating T cells, in vivo, in high quantity that are fully functional whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit www.inovio.com.

CONTACTS:
Bernie Hertel

Inovio Pharmaceuticals

+1  858-410-3101

bhertel@inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, our Form 10-Q for the quarter ended June 30, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Neomoetals {ASX: MTL} have confirmed that the shareholders of Chinese based Ganfeng have approved the transaction with Neometals for the Mount Marion lithium project.

The final hurdle is for the approval of the Jiangxi regional government.

Mt Marion Lithium Project – Ganfeng shareholder approval

Neometals Ltd and Mineral Resources Limited refer to their previous announcement regarding the execution of formal agreements with China’s second largest lithium producer, Jiangxi Ganfeng Lithium Co., Ltd, in respect of Ganfeng’s equity investment in the Mount Marion Lithium Project.

Neometals and MIN are pleased to advise that Ganfeng’s shareholders today approved the transactions contemplated by the formal agreements. This satisfies the condition precedent in the formal documents for receipt of Ganfeng shareholder approval.

The formal agreements remain conditional upon Ganfeng receiving approval of the transaction from the Jiangxi Provincial Government, which is due to be completed within the next week.

Subject to the above condition, financial close of the transaction is expected to occur in early October 2015.

Inovio Pharmaceuticals Inc {NASDAQ: INO} were delighted to announce that their COO, Dr. Ninjan Sardesai, has been awarded the title of one of PharmaVoice’s “top 100 inspiring leaders of 2015”

This is a reward for his innovation, positive contributions, and innovative thinking.

Inovio’s Chief Operating Officer Selected by PharmaVoice as one of the Most Inspirational Leaders in the Global Industry

PLYMOUTH MEETING, Pa. – September 15, 2015 – Inovio Pharmaceuticals {NASDAQ: INO}  announced today that PharmaVoice, one of the leading industry publications in the life sciences industry, has selected Dr. Niranjan Sardesai as one of its 100 most inspiring leaders of 2015.

Dr. Sardesai is the Chief Operating Officer of Inovio, a leading developer of innovative cancer and infectious disease treatment and preventive therapies. Those chosen for this elite group are selected for their positive contributions as leaders who think differently, address the big challenges facing the industry, and lead teams through inspiration. These leaders will gather in New York City on September 17, 2015 for a celebration of their selection.

Dr. Sardesai has broad operating and consulting experience in biotechnology and pharmaceuticals. He is responsible for leading the company’s product development programs in infectious disease and cancer immunotherapies and delivery systems. He has secured over $130 million in non-dilutive funding through government and NGO grants and contracts and was Inovio’s lead executive in completing Inovio’s two big pharma licensing deals with Roche and MedImmune in the last two years.

Under his leadership the company has advanced immunotherapy programs for cervical dysplasia, HIV, and cancers that are now in clinical studies. He currently serves as the principal investigator on an NIAID-funded HVDDT contract for the development of HIV vaccines and DARPA-funded Ebola vaccine and therapeutics programs.

Prior to Inovio, Dr. Sardesai oversaw R&D and expansion of the oncology portfolio at Fujirebio Diagnostics, Inc. Products developed under his leadership include new-to-the-world tests for mesothelioma (MESOMARK™), bladder cancer and a multi-marker test for ovarian cancer. He has authored over 40 peer-reviewed publications, presented at over 75 invited lectures and presentations, and filed several patents.

Dr. Sardesai said, “I am honored to be named as one of the 100 most inspiring people in the life science industry. This prestigious recognition by PharmaVoice has been possible because of the dedication of the Inovio people in our R&D, business development and commercial functions.”

Dr. J. Joseph Kim, President and CEO, said, “According to PharmaVOICE, their 100 Award is a means to celebrate the men and women who provide inspiration to their peers, colleagues, and companies through their innovative and motivation approaches to addressing the industry’s myriad challenges. We knew that about Niranjan already, and all of us at Inovio are proud that he has been counted among these honoured few.”

Established more than 10 years ago by PharmaVoice magazine, the PharmaVoice 100 is an annual list of individuals recognized for their positive contributions to the life science industry. Selected from thousands of nominations, the distinguished honorees are selected based on substantive accounts describing how they have inspired or motivated their colleagues, peers, and even competitors, have affected positive changes in their own organizations, as well as give back to their communities and other philanthropic causes.
About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that is generating T cells, in vivo, in high quantity that are fully functional whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit www.inovio.com

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals

+1 858 410 3101

bhertel@inovio.com

Inovio Pharmaceuticals {NASDAQ: INO} have reported a successful phase 2b trial for its HPV immunotherapy.

The highly respected medical journal The Lancet has reported the success of the HPV trial.

Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of its HPV Immunotherapy in The Lancet

Distinguished medical journal reports killer T cells produced by immunotherapy regress high grade cervical neoplasia and clears HPV infection

 
PLYMOUTH MEETING, Pa. – September 17, 2015 – Inovio Pharmaceuticals, Inc. {NASDAQ: INO} announced today that The Lancet, one of the world’s leading medical journals, published a peer-reviewed article detailing the successful results of its phase 2b trial with VGX-3100 in treating women with high grade cervical neoplasia.

Previously, medical researchers have tried to stimulate therapeutic immune responses against the human papillomavirus (HPV) and cervical lesions with little success. This publication details that VGX-3100, a first-in-class product for treating high grade cervical neoplasia associated with HPV, is the first therapy to demonstrate that activated killer T cells induced in the body have the power to clear neoplastic lesions as well as the virus which caused the disease.

Dr. J. Joseph Kim, Inovio’s President and CEO, said, “Inovio’s SynCon® products have overcome the elusive and difficult challenge of generating activated killer T cells in the body which clear established disease as well as eradicate cancer-causing HPV virus.”

“Building on this proof-of-concept phase 2b study, Inovio is mobilizing to initiate our phase 3 trial for VGX-3100 next year. We are also advancing our two major immunotherapy partnerships, one with MedImmune and another with Roche, as well as driving forward multiple clinical and preclinical cancer products based on our core SynCon® platform.”

Commenting on Inovio’s HPV results, two senior investigators at the U.S. National Cancer Institute Division of Cancer Epidemiology & Genetics (Dr. Mark Schiffman and Dr. Nicolas Wentzensen) wrote in The Lancet: “The current trial represents a major breakthrough and proof-of-principle that therapeutic HPV vaccination is feasible. More broadly, the trial shows that it is possible to boost immune clearance of HPV among women who initially failed to control infection.”

Dr. Mark L. Bagarazzi, Inovio’s Chief Medical Officer and the senior author of The Lancet article, said, “For women with cervical dysplasia there is no alternative treatment except for surgery – a procedure that can bring side effects such as bleeding and fertility complications. Our study of VGX-3100 provides hope for women that a safe, non-surgical option will be available to them.”

Results of the trial were reported in the article entitled, “Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomized, double-blind, placebo-controlled phase 2b trial,” by C. Trimble, et al. Dr. Cornelia Trimble, Professor of Gynecology and Obstetrics, Oncology, and Pathology at Johns Hopkins School of Medicine, was the principal investigator for the study.

Specifically, the phase 2b trial showed that histopathological regression of high grade cervical neoplasia (CIN2/3) to low grade neoplasia (CIN 1) or no disease occurred in a significantly higher percentage of VGX-3100 recipients compared with placebo recipients. Furthermore, concomitant histopathological regression and clearance of HPV occurred in a significantly higher percentage of VGX-3100 recipients compared with placebo recipients. HPV-specific CD8+ “killer T cells” were also generated in the blood as well as a substantial infiltration of CD8+ cells in the cervical tissue of VGX-3100 recipients, underscoring the role played by Inovio’s best-in-class T-cell responses. VGX-3100 was safe and generally well-tolerated.

In VGX-3100-treated women who regressed their lesion, most (43 out of 53) completely cleared their lesions to normal (complete response). Moreover, eighty percent of VGX-3100-treated women who regressed their lesion also eradicated the infecting HPV genotype (i.e. 16 or 18) in the cervix. This is an important outcome as persistence of the virus is associated with recurrence of the disease. All data analyzed per protocol or modified intent to treat were similar with equal statistical significance.

Analyses of patient immune responses showed that overall antigen-specific T cell levels in women treated with VGX-3100 were greater than those treated by placebo at all observation periods. At week 14, T cell levels in women treated with VGX-3100 were ten times greater than those in the placebo group.

Patients who regressed their lesions had higher frequencies of HPV-specific CD8+T cells which co-expressed key molecules important in T cell killing cascade and directly correlated with clinical efficacy. Specifically, we determined that higher levels of CD8+ killer T cells which co-expressed checkpoint molecule CD137 on their surface as well as the cytolytic protein perforin could be a predictive tool for efficacy. As a strong activation marker for CD8+ T cells, stimulation through CD137 has been shown in some systems to confer resistance of CD8+ T cells to the suppressive activity of regulatory T cells and its presence can identify tumor reactive T cells. Perforin is a pore-forming protein deployed by killer T cells to bore holes into the target cell’s plasma membrane and destroy the cell. In fact, the difference in frequencies of CD8+ cells expressing CD137 and perforin was greatest in patients who had both regressed their lesions and cleared HPV compared to patients who did not.

This is the first publication to our knowledge that demonstrates the correlation of antigen-specific CD8 T cells directly to clinical efficacy. Inovio has successfully identified several key biomarkers of killer T cells which can be used to predict the clinical efficacy of VGX-3100 as well as other immunotherapies in future clinical studies.

About VGX-3100

Inovio’s VGX-3100 is an immunotherapy containing two DNA plasmids targeting the E6 and E7 oncogenes of HPV types 16 and 18. These oncogenes are responsible for transforming HPV-infected cells into pre-cancerous and cancerous cells. The treatment is administered to patients by injection into muscle (typically in the arm), followed by electroporation using Inovio’s CELLECTRA® device. VGX-3100 has been shown to induce a robust immune response against the E6 and E7 oncogenes associated with HPV types 16 and 18.

About HPV and Cervical Dysplasia

Human papillomavirus (HPV) is the most common sexually transmitted disease. At any given time, approximately 11% percent of the world population is infected with HPV. Roughly 75% or less of HPV 16/18 infections are cleared by naturally occurring immune responses in women of all ages.

Persistent HPV infection can lead to dysplasia, or premalignant changes, in cervical cells. HPV types 16 and 18 cause 70% of cervical dysplasia and cervical cancer cases. Each year in the United States, 1.4 million women are diagnosed with CIN1 and 300,000-400,000 women are diagnosed with CIN 2/3. All cervical cancers arise from untreated CIN2/3.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that is generating T cells, in vivo, in high quantity that are fully functional whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit www.inovio.com

CONTACT:
Investors: Bernie Hertel, Inovio Pharmaceuticals,

+1 858 410 3101

bhertel@inovio.com

Carlisle Goldfields {TSX.V: CGJ} have confirmed that they will continue their 2015 drill program in Q4 2015, drilling 5,500 metres at Lynn lake outside the feasibility study area.

Additionally, the company have confirmed the discovery of the Little Wing Gold prospect.

Carlisle announces exploration drilling at Lynn lake in Q4 2015, plus discovery of the Little Wing Gold Prospect.

2015-09-15 – News Release

Mr. Abraham Drost reports

Carlisle Goldfields Ltd.{TSX.V: CGJ}  is continuing the 2015 special exploration drill program outside the feasibility study area at the Lynn Lake joint venture claims at Lynn Lake, Man.

The fourth-quarter 2015 program will consist of a further approximately 5,500 metres of drilling on four target areas in the South Belt identified through field sampling and data compilation (see the table). Additional first-quarter 2016 winter drilling is anticipated on two areas in the North Belt pending induced-polarization results, including the newly discovered Little Wing gold prospect and the historic Arbour Lake prospect.

The discovery of the Little Wing gold prospect in highly altered angular float boulders and outcrop by senior project geologist Ben Kuzmich demonstrates the considerable exploration potential remaining in the Lynn Lake belt between the Farley Lake and MacLellan gold deposits. The Little Wing prospect is hosted in granitoid intrusive rocks within the North Belt Agassiz metallotect and exhibits surface assay values of up to 361 grams per tonne of gold.

Carlisle and its joint venture partner Alamos Gold Inc. are jointly financing the $4-million special exploration program outside the feasibility study area in calendar 2015. Carlisle is the operator of special exploration activities on the balance of the 39,000-hectare LLJV claims.

Carlisle’s joint venture partner Alamos previously acquired a 25-per-cent interest in the LLJV and has the right to increase its interest to 51 per cent by spending $20-million on the advancement of a feasibility study on the MacLellan and Farley Lake deposits by Nov. 10, 2017. Alamos may increase its interest in the LLJV to a maximum of 60 per cent by delivering a compliant feasibility study within the same period.

Carlisle’s President and CEO Abraham Drost commented that: “Results from geological mapping, prospecting and sampling during the 2015 special exploration program have highlighted the potential for additional mineralization in the South Belt and North Belt greenstone assemblage of the Lynn Lake gold camp. We are particularly excited by the discovery of the new Little Wing prospect”.

“The fourth-quarter 2015 drilling campaign will also better define evident continuity of mineralization between the Burnt Timber and Linkwood deposits within the Johnson shear and related splay structures in the South Belt. It is our continuing belief that the Burnt Timber and Linkwood deposits are part of a larger gold system in this area of the Johnson shear. We expect that the area will ultimately be subjected to a definitive feasibility study to assess future pipeline development potential for the LLJV. We look forward to sharing our plans with participants at the 2015 precious metal summit, Colorado, Sept. 16 to 18, 2015.”

Special exploration results from the Lynn Lake gold camp

Drill target: Arbour lake (North Belt)

Highlights:  Of the 55 surface samples collected from the quartz-diorite intrusive, 10 assayed more than 0.4 gram per tonne gold, including a 1.3 g/t Au chip sample across a 2.5-metre-wide north-trending quartz vein with disseminated chalcopyrite-bornite and 13.9 g/t Au from a heavily silicified quartz-diorite grab sample in the immediate wall rock to the vein. This vein is coincident with a 340 m long north-trending airborne electromagnetic conductor identified in the regional airborne survey flown this past spring.

Planned work:  A work permit has been submitted for a fourth-quarter 2015 ground IP survey to define the extent of the north-south mineralised structures. Follow-up drilling, pending IP results, is planned for first-quarter 2016.

Drill target: Little Wing (new discovery) (North Belt)

Highlights:  Of the 39 surface grab samples collected to date, 16 assayed more than 0.4 g/t Au, including three samples between one g/t Au and two g/t Au and five samples with more than five g/t Au, including up to 361 g/t Au from a narrow quartz vein with abundant VG. High-grade mineralisation is hosted within angular hematite, silica-sericite-altered granite boulders interpreted to be frost-heaved subcrop. Mapping in the area has identified several similarly altered granite/granodiorite outcrops up to 450 m along strike to the east, which returned low-grade gold mineralisation in the range of 0.2 g/t Au to 0.7 g/t Au.

Planned work:  A work permit has been submitted for the fourth-quarter 2015 ground IP survey to define the extent of the mineralised trend. Follow-up drilling, pending IP results, is planned for first-quarter 2016.

Drill target: Johnson vein (South Belt)

Highlights:  Of the 36 surface grab samples collected to date, 13 assayed more than 0.4 g/t Au, including four samples between one g/t Au and two g/t Au and six samples with more than five g/t Au taken from quartz-sulphide veins up to 60 centimetres wide exposed in historic trenches along the Johnson shear zone.

Planned work:   Three drill holes along the eastern margin of the Johnson and Johnson option property will be drilled in fourth-quarter 2015 to test the continuity of mineralisation along the Johnson shear zone in this area.

Drill target: Maynard (South Belt)

Highlights:  DV15-04, drilled this past spring, returned 1.6 g/t Au over 10.6 m from 35 m depth and 5.6 g/t Au over 5.6 m from 151 m depth. DV15-05, drilled 100 m to the east, returned 5.0 g/t Au over 4.5 m from 107 m depth (see news release dated June 10, 2015). Both zones are coincident with a one-kilometre-long pronounced IP chargeability anomaly, which has not been drilled tested to the east.

Planned work:  Four holes along the eastern continuation of the IP anomaly will be drilled in fourth-quarter 2015 to test the extension of mineralisation up to 500 m along strike to the east.

Drill target: 12-13 zone (South Belt)

Highlights:  Historic intersections in the 12-13 zone of up 1.3 g/t Au over six m and 1.0 g/t Au over 10.5 m demonstrate a mineralisation style and distribution similar to that of the western portion of the Burnt Timber deposit. The 12-13 zone is coincident with an 800 m long pronounced IP chargeability anomaly 100 m southwest of the Burnt Timber deposit.

Planned work:  Nine holes will test the possible strike extension of the existing Burnt Timber National Instrument 43-101-compliant resource for a strike length of 1.1 kilometres to a vertical depth of 200 m. The drill program will also test the existence of mineralised zones with a possible strike length of 800 m, located 100 m to the southwest of the Burnt Timber resource, as suggested by 13 historic drill holes into the 12-13 zone.

Drill target: Lost Lake (South Belt)

Highlights:  The Lost Lake target overlies a 2.3-kilometre-long pronounced IP chargeability anomaly within the Johnson shear zone identified in the Dunvegan IP survey this spring. Historic drilling in the area returned up to 4.6 g/t Au over 4.8 m within a silica-carbonate flooded deformation zone.

Planned work:  Approximately seven holes will be drilled in fourth-quarter 2015 to test the IP anomaly along 200 m to 300 m wide step outs.

Quality assurance/quality control

Carlisle’s special exploration program was carried out under the direction of Ryan Weston, PGeo, chief geologist of Carlisle and a qualified person as defined by National Instrument 43-101, who has reviewed and approved the technical content of this news release.

Samples were transported directly in secure containers from the Carlisle Goldfields site in Lynn Lake, Man., to the TSL Laboratories in Saskatoon, Sask. TSL, which is an accredited ISO/IEC 17025 lab, assayed the samples using standard fire assay methods with a gravimetric finish. Certified standards are placed in the sample stream at a rate of one standard per 20 samples. Certified blanks are placed in the sample stream at a rate of one blank every 40 samples. Results are analyzed for acceptance at the time of import. All standards associated with the results in this news release were determined to be acceptable within the defined limits of the standard used.

Special exploration program on LLJV lands

Carlisle previously announced a 3,500 m drill program in the Dunvegan area along strike to the west of the Linkwood and Burnt Timber deposits on the Johnson shear structure within the Lynn Lake greenstone belt. Two geological/prospecting field crews were on the LLJV claims during the summer field season conducting exploration and evaluation of a variety of newly discovered and historical gold occurrences for additional drill testing.

The Burnt Timber deposit has a previously reported (Dec. 2, 2013) inferred open-pit-constrained mineral resource of 23.4 million tonnes at an average grade of 1.04 g/t gold, and the Linkwood deposit has an inferred open-pit-constrained mineral resource of 21.0 million tonnes at an average grade of 1.16 g/t gold.

The LLJV previously conducted a high-resolution airborne magnetic and electromagnetic geophysical survey over the entire property and induced-polarization ground surveys to assist with drill target identification. Structural analysis of the airborne geophysical data was completed by SRK Mining Consultants. Drill targets were selected through a ranking system evaluating favourable structural and lithological targets identified in the new airborne and ground geophysics coincident with historical gold occurrences in the belt.

We seek Safe Harbor.

Barkerville Gold Mines {TSX.V: BGM} have announced a high grade discovery some 500 Metres from their Bonanza ledge open pit mine.

The discovery reported “significant assays” – See article for full details.

Comment

After the upheaval of the last couple of years, Barkerville is finally getting back on track, and making some decent discoveries at their property.

That the property was highly prospective for gold was never really in doubt in my opinion, what did seem to be the problem was poor execution, and a lack of urgency to commence production, particularly whilst gold prices were at their highs.

The dark cloud on the horizon is the debt to Sprott, and it remains to be seen how that plays out. Until then, potential investors may play a waiting brief.

——–

BGM DISCOVERS NEW HIGH GRADE GOLD HORIZON ON BARKERVILLE MOUNTAIN

Barkerville drills two m of 14.07 g/t Au at Cariboo

2015-09-15 11:24 ET – News Release

Barkerville Gold Mines {TSX.V: BGM}. has discovered a new high-grade gold horizon (the KL horizon) 500 metres east of the Bonanza Ledge open pit and has released additional results from the ongoing phase I drilling program on Barkerville Mountain at the company’s flagship Cariboo Gold project.

New KL horizon discovered approximately 500 metres east of the Bonanza Pit and sub-parallel to the B.C. vein, with multiple mineralised veins identified.

Significant assays include;

• 8.38 grams per ton over 1.77 metres (including 11.95 g/t over 0.79 metres), 13.47 g/t over 0.52 metres and 6.09 g/t over 0.95 metres in BGM-15-022;
• 5.65 g/t over 1.5 metres, 4.83 g/t over 4.8 metres (including 15.04 g/t over 0.8 metres, 6.01 g/t over 0.9 metres, 4.87 g/t over one metre), 8.99 g/t over one metre and 6.47 g/t over 1.2 metres in BGM-15-023;
• 6.39 g/t over 7.3 metres (including 15.63 g/t over 1.05 metres, 13.90 g/t over 0.6 metres, 15.09 g/t over 1.25 metres) and 10.33 g/t over 0.85 metres in BGM-15-024;
• 3.55 g/t over 9.8 metres (including 7.39 g/t over 0.8 metres, 5.58 g/t over 4.25 metres, 7.03 g/t over 1.25 metres, 12.73 g/t over one metre), 14.07 g/t over two metres (including 9.09 g/t over one metre, 19.04 g/t over one metre) in BGM-15-025;
• 13.95 g/t over 1.9 metres (including 15.34 g/t over 1.6 metres) in BGM-15-027;
• KL horizon outlined over a strike length of 60 metres and a vertical depth of 120 metres, and remains open in all directions.

The location of the new KL horizon was identified by previous operators by a marked, auriferous soil anomaly and was subsequently exposed by mechanical stripping in 2012. Surface sampling of the exposed bedrock yielded grab assays up to 167.42 g/t (4.88 ounces per ton) gold in an undrilled swarm of sulphide-bearing quartz veins. The first pass of 2015 phase I drilling has outlined the horizon over a strike length of 60 metres and to a vertical depth of 120 metres. The KL horizon remains open at depth and along strike and is interpreted to represent a previously unidentified auriferous structure sub-parallel to the BCV.

Tom Obradovich, president and chief executive officer of the company, commented: “We are very pleased to have made a new discovery in a previously unexplored area which has never been drilled. The high grades we encountered on this first pass of shallow drilling and the consistency of the mineralisation supports our belief that we are in the early stages of developing a large gold system.”

Diamond drill holes BGM-15-022 through BGM-15-027 were designed to test the area devoid of historic drilling in the newly discovered KL horizon, while diamond drill holes BGM-15-014 through BGM-15-021 were designed to explore the down dip extensions of the TC area vein sets. The results of these diamond drill programs are presented below in Table 1. A drill hole location plan map available on the company’s website.

Two rigs are currently active systematically grid drilling the B.C. vein on 50-metre centres. A third drill rig has been delivered and is being utilized to further expand the newly discovered KL horizon as well as investigate additional soil anomalies on Barkerville Mountain.

Qualified persons

Exploration activities at the Cariboo Gold project are jointly administered on site by the company’s project managers Maggie Layman, PGeo, and Wanda Carter, PGeo. As per National Instrument 43-101, Standards of Disclosure for Mineral Projects, Paul Geddes, PGeo, vice-president of exploration, is the qualified person for the company and has prepared, validated and approved the technical content of this news release. The company strictly adheres to CIM Best Practices guidelines in conducting, documenting, and reporting its exploration activities on the Cariboo Gold project.

Quality assurance — quality control

Once received from the drill and processed, all drill core samples are sawn in half, labelled and bagged. The remaining drill core is subsequently stored on site at the company’s secure facility in Wells, B.C. Numbered security tags are applied to lab shipments for chain of custody requirements. The company inserts quality control (QC) samples at regular intervals in the sample stream, including blanks and reference materials with all sample shipments to monitor laboratory performance. The QAQC program was designed and approved by Lynda Bloom, PGeo, of Analytical Solutions Ltd., and is overseen by Mr. Geddes, PGeo, vice-president of exploration.

Drill core samples are submitted to SGS Canada’s analytical facility in Burnaby, B.C., for preparation and analysis. The SGS facility is accredited to the ISO/IEC 17025 standard for gold assays and all analytical methods include quality control materials at set frequencies with established data acceptance criteria. The entire sample is crushed and 1,000 grams is pulverized.

Analysis for gold is by 50 g fire assay fusion with atomic absorption (AAS) finish with a lower limit of five parts per billion and upper limit of 10,000 ppb. Samples with gold assays greater than 10,000 ppb are reanalyzed using 50 g fire assay with gravimetric finish, as well as 1,000 g screen metallic fire assay. Samples are also analyzed using a 49 multielemental geochemical package by a four-acid digestion, followed by inductively coupled plasma atomic emission spectroscopy (ICP-AES) and inductively coupled plasma mass spectroscopy (ICP-MS).

TABLE 1: LENGTH WEIGHTED GOLD COMPOSITES FOR DRILLHOLES BGM-15-014 THROUGH BGM-15-028

Hole ID     From (m)  To (m)  Core length (m)  Au (g/t)  Au (ounce/t) Comment

BGM-15-014    32.35   33.70             1.35      8.92          0.26       TC     
Including     32.35   33.10             0.75     13.89          0.41       TC     
BGM-15-015    36.40   37.70             1.30      5.45          0.16       TC     
BGM-15-016    35.88   36.52             0.64      4.40          0.13       TC     
BGM-15-016    67.45   71.50             4.05      2.32          0.07       TC     
Including     68.46   69.50             1.04      5.74          0.17       TC     
BGM-15-016   135.13  135.90             0.77      4.38          0.13       TC     
BGM-15-017                                        Hole abandoned at 37 metres                          
BGM-15-018    50.00   51.05             1.05      2.01          0.06       TC     
BGM-15-019    46.65   47.25             0.60      4.66          0.14       TC     
BGM-15-019    48.50   50.00             1.50      9.89          0.29       TC     
BGM-15-019    60.30   69.00             8.70      2.40          0.07       TC     
Including     60.30   61.00             0.70      7.69          0.22       TC     
And           68.45   69.00             0.55      5.30          0.15       TC     
BGM-15-019   138.00  139.50             1.50      3.15          0.09      BCV    
BGM-15-019   141.00  142.50             1.50      5.86          0.17      BCV    
BGM-15-019   170.00  171.50             1.50      2.56          0.07       BL     
BGM-15-020    41.90   42.65             0.75     14.02          0.41       TC     
BGM-15-020    55.50   56.35             0.85      3.80          0.11       TC     
BGM-15-020    86.00   87.50             1.50      3.30          0.10       TC     
BGM-15-020   125.00  127.00             2.00      4.36          0.13      BCV    
BGM-15-020   133.00  134.00             1.00      3.55          0.10      BCV    
BGM-15-021                                              No significant assays                                 
BGM-15-022    22.91   23.44             0.53      4.17          0.12      KLH    
BGM-15-022    26.00   27.00             1.00      5.22          0.15      KLH    
BGM-15-022    28.75   30.52             1.77      8.38          0.24      KLH    
Including     29.73   30.52             0.79     11.95          0.35      KLH    
BGM-15-022    41.45   41.97             0.52     13.47          0.39      KLH    
BGM-15-022   127.50  128.00             0.50      3.18          0.09      KLH    
BGM-15-022   130.61  131.61             1.00      3.19          0.09      KLH    
BGM-15-022   142.99  143.97             0.98      4.28          0.12      KLH    
BGM-15-022   155.00  156.02             1.02      2.04          0.06      KLH    
BGM-15-022   177.45  178.40             0.95      6.09          0.18      KLH    
BGM-15-023     9.50   11.00             1.50      5.65          0.16      KLH    
BGM-15-023    46.20   51.00             4.80      4.83          0.14      KLH    
Including     46.20   47.00             0.80     15.04          0.44      KLH    
And           49.10   50.00             0.90      6.01          0.18      KLH    
And           50.00   51.00             1.00      4.87          0.14      KLH    
BGM-15-023    55.80   57.50             1.70      2.90          0.08      KLH    
BGM-15-023    77.50   78.50             1.00      8.99          0.26      KLH    
BGM-15-023    96.50   97.70             1.20      6.47          0.19      KLH    
BGM-15-024    34.55   36.00             1.45      3.15          0.09      KLH    
BGM-15-024    66.95   74.25             7.30      6.39          0.19      KLH    
Including     66.95   68.00             1.05     15.63          0.46      KLH    
And           68.00   68.60             0.60     13.90          0.41      KLH    
And           73.00   74.25             1.25     15.09          0.44      KLH    
BGM-15-024   110.85  111.70             0.85     10.33          0.30      KLH    
BGM-15-025    11.50   13.00             1.50      2.77          0.08      KLH    
BGM-15-025    35.20   45.00             9.80      3.55          0.10      KLH    
Including     35.20   36.00             0.80      7.39          0.22      KLH    
And           40.75   45.00             4.25      5.58          0.16      KLH    
Including     40.75   42.00             1.25      7.03          0.21      KLH    
Including     44.00   45.00             1.00     12.73          0.37      KLH    
BGM-15-025   143.00  145.00             2.00     14.07          0.41      KLH    
Including    143.00  144.00             1.00      9.09          0.27      KLH    
And          144.00  145.00             1.00     19.04          0.56      KLH    
BGM-15-026    12.50   14.00             1.50      1.31          0.04      KLH    
BGM-15-027    62.20   64.10             1.90     13.95          0.41      KLH    
Including     62.50   64.10             1.60     15.34          0.45      KLH    
BGM-15-027    73.00   86.70            13.70      1.03          0.03      KLH    
BGM-15-027   104.00  106.00             2.00      2.88          0.08      KLH    
BGM-15-027   109.50  111.00             1.50      2.39          0.07      KLH    
BGM-15-027   117.80  118.60             0.80      3.57          0.10      KLH    
BGM-15-027   130.50  132.60             2.10      3.52          0.10      KLH    



Notes: Core lengths represent 70 to 90 per cent true widths. Rock nt recovered by drilling was assigned zero grade and not
included in the composites. Top cuts have not been applied
to high grade assays. One ounce per ton is equal to 34.2857 g/t.
BCV - B.C. vein; HWV - Hanging Wall vein; KLH - KL horizon.

Condor Gold {AIM: CNR} have released a technical report of the structural nature of their La India Deposit in Nicaragua.

After their “for sale” announcement, perhaps dressing the shop window for potential suitors? This release is not aimed at investors.

15th September 2015

Condor Gold Plc.

Structural Geology Consultant’s Report on La India Project.

Condor Gold {AIM: CNR}, is pleased to announce that consultant structural geologist Dr Tony Starling of Telluris Consulting Ltd has completed a study on the structural geology of the La India Gold District.

The study represents a significant step forward in understanding both the structures that host, and the structures that offset, the gold mineralisation in the La India District. At resource scale the work will enhance and improve confidence in future resource models. At regional scale the study improves understanding of the structural framework that controlled the flow and deposition of epithermal gold. The findings will be integrated with the recently collected soil geochemical data to define and prioritise targets for further exploration for hidden deep-seated gold deposits.

Mark Child, CEO comments: “We are delighted with the results of a very detailed report on the structural geology of La India Gold District following a 12 day site visit by consultant structural geologist Dr Tony Starling. La India Project is a low sulphidation epithermal gold system, which is structurally controlled and complex e.g. the multiple phases of faulting in the historic past chanelled the upflow and precipitation of the gold bearing fluids. The study represents a significant step forward in understanding the structure that hosts the gold mineralisation at La India Project. The report details 33 exploration targets derived from the structural setting, 23 of which have known gold veining at surface. The targets require follow up work on the ground and prioritisation before an exploration programme can be planned. Summary presentations of the structural geology study and a study detailing results of the recent 55 sq km soil survey are available under the technical reports section of www.condorgold.com ”

The structural geology report draws on the most recent academic and field studies to establish the position of La India Project  within the Tertiary magmatic arc and tectonic framework. The report focuses on the better documented core resource area of La India, America and La Mestiza vein sets, and as far out as the Dos Hermanos Vein to  the southeast and the Cristalito, Real de La Cruz and Cacao prospects to the north and east. This area encompasses the entire independent mineral resource estimate for la India Project which currently stands at 18.1 M tonnes at 4.0 g/t gold containing 2.32 M oz gold.

The La India District has been subject to three principal deformation phases during deposition of the host Coyol Group volcanic rocks in the early to mid-Miocene.
D1 occurred during the mid-Miocene as NNE-SSW directed extension caused by subduction zone roll-back and then rebound from slab detachment. This event imparted the dominant WNW structural grain and development of NNE transfer faults such as the Highway Fault. The emplacement of a series of rhyolite flow domes such as at Real de La Cruz and Santa Barbara appear to be associated with the transfer faults. This event is considered pre-gold mineralisation, although gold mineralisation at the end of the event on WNW and E-W veins is not discounted.

D2, the main gold mineralising event, is likely to have occurred sometime during the mid- to late-Miocene (around 9.5 to 3.8 million years ago) during the slab detachment phase and a pause in volcanism. Regional extension rotated clockwise to an ENE to E-W direction likely due to the relative easterly motion of the Caribbean Plate. During this phase, the WNW structures were reactivated as dextral transtensional faults resulting in dilation and concentration of gold mineralisation along NNW striking jogs and newly created NNW-trending extensional faults. The development of steeply dipping to near vertical high-grade shoots on the La India Vein is attributed to the interaction between pre-existing dextral transtensional WNW faults and the more dilational NNW-striking La India fault. Pre-existing structures such as the Highway Fault were reactivated again as transform or transtensional faults. Another pre-existing deep seated NNW structural fabric visible in geophysics and to a lesser extent topography appears to be associated with the principal La India, America and La Mestiza vein sets and may have formed a deep-seated hydrothermal fluid pathway.

D3, which started in the early Pliocene and continues to this day, was initiated by a return to a subduction zone regime and the subsequent collision of the Cocos Ridge with the Caribbean Plate at Costa Rica resulting in dextral strike-slip motion along the forearc zone in Nicaragua. At La India this event is seen as a return to N-S to NNE-SSW directed extension that implies a partitioning of oblique subduction into pure strike-slip and extensional components. Reactivation of some fault veins occurred during this phase with graben development in the centre of the America Vein Set and the deep-seated El Tanque Graben, suggesting significant extensional movement. This phase is also associated with reactivation of the NNE Highway Fault and another parallel fault running up to Real de La Cruz, this time as transtensional faults with downthrow movement to the east of a large block incorporating La India South – Mojarra, Central Breccia – Cacao and the Real de La Cruz and Santa Barbara areas (Figure 4). Gold mineralisation channelled by these faults at Central Breccia, Cacao and possibly at Real de la Cruz are interpreted as the upper levels of epithermal mineralisation, perhaps reflecting hydrothermal upflow zones. Some important prospect-scale structural interpretations associated with D3 structures include:
• Listric faulting and rotation of hanging wall blocks as imbricate listric fault blocks on the La India structure as evidenced by inclined bedding.
• The Highway Fault terminates against the La India Fault along the hanging wall of the vein with extension being absorbed by down throw of La India South. This provides an elegant explanation for the deeper-seated mineralisation at La India South and the position of the andesite host.
• The high-grade gold mineralised breccia at Real de La Cruz is gold mineralisation on a NNE fault parallel to the Highway Fault whilst the E-W to WNW trending stockwork veinlets reflect the regional structural grain.

Future gold exploration, particularly for hidden deep-seated gold mineralisation should target the NNW striking jogs on WNW faults, NNW-trending linking faults that formed dilational zones in the D2 deformation phase, and also the intersection of NNE faults such as the Highway Fault with cross-cutting NNW- and WNW-trending faults. Downthrow of the rock masses to the east of the Highway Fault, the centre of the America Vein Set and the deep-seated El Tanque Graben suggests that these areas are likely to have suffered the least erosion and are therefore the most likely to have preserved the entire boiling zone beneath surface. Vein textures of surface exposures of the known gold prospects within these downthrown blocks such as Central Breccia, Cacao and Real de La Cruz confirm the high-level of gold mineralisation and soil geochemistry at El Tanque supports this block as exploration targets for hidden deep seated gold mineralisation. Thirty-three targets that meet these structural criteria have been identified in the study, twenty-three of which have known quartz veining at surface. All the targets are being assessed by detailed geological field mapping with the structural targets that occur in the downthrown blocks and with anomalies identified in the regional soil geochemical data prioritised for follow-up exploration.

Telluris Consulting Ltd

Dr Tony Starling is founder and Managing Director of Telluris Consulting Ltd. Telluris Consulting is a geological consultancy established in 1993 that specialises in the application of structural and alteration studies with bespoke image processing with extensive experience in the Central America. Dr Starling has reviewed the information and consents to the inclusion in this announcement of the opinions and figures that can be attributed to the Telluris study.

Competent Person’s Declaration
The information in this announcement that relates to the mineral potential, geology, Exploration Results and database is based on information compiled by and reviewed by Dr Luc English, the Country Exploration Manager, who is a Chartered Geologist and Fellow of the Geological Society of London, and a geologist with twenty years of experience in the exploration and definition of precious and base metal mineral resources. Luc English is a full-time employee of Condor Gold plc and has sufficient experience which is relevant to the style of mineralization and type of deposit under consideration, and to the type of activity which he is undertaking to qualify as a Competent Person as defined in the June 2009 Edition of the AIM Note for Mining and Oil & Gas Companies. Luc English consents to the inclusion in the announcement of the matters based on the information in the form and context in which it appears and confirms that this information is accurate and not false or misleading.

Technical Glossary
Breccia A rock made up of angular rock fragments cemented together by a finer grained matrix
Deformation Phase A period of time, typically millions of years, during which a rock mass is subjected to stress in a particular direction. The stress direction will typically result in deformation of the rocks either as brittle faults and fractures or as more ductile deformation such as folding and shearing.
Dextral Left lateral movement, such that if the observer were to observe a point on the other side of the movement plane then that point would move from right to left.
Dip A line directed down the steepest axis of a planar structure including a planar ore body or zone of mineralisation. The dip has a measurable direction and inclination from horizontal.
Down-throw Referring to the rock that has moved downwards on a fault relative to the other side.
Down-dip Further down towards the deepest parts of an ore body or zone of mineralisation.
Epithermal Mineral veins and ore deposited from fluids at shallow depths at low pressure and temperatures ranging from 50-300°C
Fault The plane along which two rock masses have moved or slide against each other in opposing directions
Fault breccia A rock made up of angular rock fragments cemented together by a finer grained matrix formed by the mechanical grinding of rock along the fault plane during movement of the fault.
Geochemistry The study of the elements and their interaction as minerals to makeup rocks and soils.
Geophysics The measurement and interpretation of the earth’s physical parameters using non-invasive methods such as measuring the gravity, magnetic susceptibility, electrical conductivity, seismic response and natural radioactive emissions.
Graben A geological structure formed as a response to extensional forces in the Earth’s crust whereby a series of faults develop which converge at depth along an axis perpendicular to the direction of extension. The wedge shaped rock masses between the faults at the centre of the axis sink to fill the space caused by the ‘pulling-apart’ of the crust.
Hanging wall The rock adjacent to and above an ore or mineralised body or geological fault. Note that on steeply-dipping tabular ore or mineralised bodies the hanging wall will be inclined nearer to the vertical than horizontal.
Horse Tail Structure Describing the lateral termination of a geological fracture or fault that splits into a several low-angle to near-parallel fractures and faults arranged in the form resembling a horse’s tail in plan view.
Hydrothermal Hot water circulation often caused by heating of groundwater by near surface magmas and often occurring in association with volcanic activity. Hydrothermal waters can contain significant concentrations of dissolved minerals.
Listric Fault Where the plane along which two rock masses have moved or slide against each other in opposing directions is steeper in the upper parts and bends to be progressively shallower at depth. These faults typically form under an extensional stress regime.
Magnetic (aeromagnetic) survey The measurement of the magnetic properties of the earth surface as controlled by the concentration and distribution of magnetic minerals, particularly magnetite, in the rock. Rocks containing higher levels of iron, such as mafic igneous rocks or some sedimentary rocks will have a higher magnetic susceptibility than felsic igneous rocks, siliciclastic and carbonate sediments and their metamorphic derivatives.
Miocene An epoch of time between approximately 5.3 and 23.0 Million years ago.
Mineral Resource A concentration or occurrence of material of economic interest in or on the Earth’s crust in such a form, quality, and quantity that there are reasonable and realistic prospects for eventual economic extraction. The location, quantity, grade, continuity and other geological characteristics of a Mineral Resource are known, estimated from specific geological knowledge, or interpreted from a well constrained and portrayed geological model
Mineral Reserve The economically mineable part of a Measured and/or Indicated Mineral Resource. It includes diluting materials and allowances for losses, which may occur when the material is mined. Appropriate assessments and studies have been carried out, and include consideration of and modification by realistically assumed mining, metallurgical, economic, marketing, legal, environmental, social and governmental factors. These assessments demonstrate at the time of reporting that extraction could reasonably be justified. Ore Reserves are sub-divided in order of increasing confidence into Probable Ore Reserves and Proved Ore Reserves.
Pliocene An epoch of time between approximately 2.6 and 5.3 Million years ago.
Radiometric Also known as gamma ray spectrometry, is the measure of natural radiation on the top 30-45cm of the earth’s surface. The abundance of the three naturally occurring radioactive elements, potassium (K), thorium (Th) and uranium (U), is proportional to the abundance of minerals containing those elements. This information can be used in mapping the surface geology including the definition of areas of potassium enrichment related to hydrothermal alteration.
Rhyolite A silica and -rich volcanic igneous rock dominated by fine-grained quartz and feldspar crystals.
Rock chip A sample of rock collected for analysis, from one or several close spaced sample points at a location. Unless otherwise stated, this type of sample is not representative of the variation in grade across the width of an ore or mineralised body and the assay results cannot be used in a Mineral Resource Estimation
Subduction Zone Where the edge of a Tectonic plate (slab of the Earth’s crust) dips under the over-riding edge of the neighbouring plate and is pushed into the underlying hot molten mantle within which the leading edge of the subducting plate eventually melts.
Stockwork Multiple connected veins with more than one orientation, typically consisting of millimetre to centimeter thick fracture-fill veins and veinlets.
Strike length The longest horizontal dimension of an ore body or zone of mineralisation.
Tectonic Plate Referring to the slabs of solid crustal rock hundreds to thousands of kilometres in lateral dimensions and tens of kilometres thick that form the Earth’s crust and are capable of moving very slowly against each other, replenished with solidified deep mantle material where they move apart or forming mountain belts or subducting one beneath another where they collide.
Transfer or Transform Fault A surface along which two adjacent rock masses have moved in a lateral direction. Tranform faults are typically steeply-dipping to vertical.
Transtensional Fault A surface along which two adjacent rock masses have moved in an oblique lateral and vertical direction under a stress regime that is extensional oblique to the strike of the fault plane.
Vein A sheet-like body of crystallised minerals within a rock, generally forming in a discontinuity or crack between two rock masses. Economic concentrations of gold are often contained within vein minerals.

– Ends –
For further information please visit www.condorgold.com or contact:

Condor Gold Plc
Mark Child, Executive Chairman and CEO
0207 493 2784

Luc English, Country Manager Nicaragua
+505 8854 0753

About Condor Gold Plc:
Condor Gold plc was admitted to AIM on 31st May 2006. The Company is a gold exploration and development company with a focus on Central America.
Condor completed a Pre-Feasibility Study (PFS) and two Preliminary Economic Assessments (PEA) on La India Project in Nicaragua in December 2014. The PFS details an open pit gold mineral reserve of 6.9M tonnes at 3.0g/t gold for 675,000 oz gold producing 80,000 oz gold p.a. for 7 years. The PEA for the open pit only scenario details 100,000 oz gold production p.a. for 8 years whereas the PEA for a combination of open pit and underground details 140,000 oz gold production p.a. for 8 years. La India Project contains a total attributable mineral resource of 18.4Mt at 3.9g/t for 2.33M oz gold and 2.68M oz silver at 6.2g/t to the CIM Code.

In El Salvador, Condor has an attributable 1,004,000 oz gold equivalent at 2.6g/t JORC compliant resource. The resource calculations are compiled by independent geologists SRK Consulting (UK) Limited for Nicaragua and Ravensgate and Geosure for El Salvador.

Disclaimer

Neither the contents of the Company’s website nor the contents of any website accessible from hyperlinks on the Company’s website (or any other website) is incorporated into, or forms part of, this announcement.

Beaumont Cornish Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively as Rule 3 adviser to Condor Gold plc and no one else in connection with the Strategic Review (leading to an Offer Period) (the “Strategic Review”) and will not be responsible to anyone other than Condor Gold plc for providing the protections afforded to clients of Beaumont Cornish Limited nor for providing advice in relation to the Strategic Review. Neither Beaumont Cornish Limited nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Beaumont Cornish Limited in connection with this Announcement, any statement contained herein, the Strategic Review or otherwise.

The Directors of the Company accept responsibility for the contents of this announcement.

A copy of this announcement will be made available subject to certain restrictions relating to persons resident in restricted jurisdictions on Condor Gold’s website (www.condorgold.com), under the “Investor Relations” section no later than 12 noon on *** September 2015

Scorpio Gold Corp. {TSX.V: SGN} has released further drill results from their Bluelite satellite deposit located at Mineral Ridge, Nevada.

As with previous drill results at Bluelite, Scorpio have located good grades at a shallow depth.

Scorpio Gold Reports Results from 2015 Expansion Drilling at the Bluelite Satellite Deposit, Mineral Ridge Project, Nevada
Vancouver, September 14, 2015 – Scorpio Gold Corp.({TSX.V: SGN} reports additional results from the 2015 expansion drilling program on the Bluelite satellite deposit at its 70% owned Mineral Ridge project, located in Nevada.

The 2015 expansion program at Bluelite has included infill, development and exploration drilling to expand and upgrade the current mineral reserve and resource base for the deposit and potentially extend life of mine.

All of the holes presented in Table 1 are step-out exploration holes located to the south-southwest and southeast of currently defined resources for the Bluelite deposit. Drilling has now outlined a broad area of mineralisation extending 250 meters to the south-southwest of the Bluelite deposit and 500 meters southeast along the NW Brodie trend.

Management believes that results received to date from the 2015 drilling program should positively impact the existing resource base at the Bluelite deposit.

Pre-production development work at the Bluelite deposit began in May 2015 with the pre-stripping of waste material. The pit entered production on July 1, 2015 and as of the end of August, 53,086 ore tons at an average grade of 1.82 g/t gold, and 655,921 waste tons have been mined.

Highlights from this latest phase of exploration drilling at the Bluelite deposit include:
MR151445: 3.26 g/t gold over 4.57 meters
MR151574: 1.25 g/t gold over 4.57 meters
MR151578: 3.14 g/t gold over 3.05 meters
MR151579: A1.47 g/t gold over 6.10 meters
MR151603: 1.60 g/t gold over 4.57 meters
MR151605: 1.99 g/t gold over 7.62 meters
MR151691: 2.25 g/t gold over 6.10 meters
MR151695: 1.18 g/t gold over 6.10 meters
MR151696: 1.46 g/t gold over 3.05 meters

A drill hole location map is available at: DH Plan

Table 1. Bluelite Deposit Target Area – Significant Drill Results

All holes presented in Table 1 were completed by reverse circulation (RC) drilling. True width is estimated at 80-100% of downhole width. Analytical results were performed by American Assay Laboratory Inc. in Sparks, Nevada, an ISO/IEC 17025:2005 accredited facility. External check assays to verify lab accuracy are routinely completed by ALS Chemex, an ISO 9001:2000 certified and ISO/IEC 17025:2005 accredited facility.

Further details are presented in the Company’s quality assurance and quality control program for the Mineral Ridge project available at: MR QAQC.

About Scorpio Gold

Scorpio Gold holds a 70% interest in the producing Mineral Ridge gold mining operation located in Esmeralda County, Nevada with joint venture partner Waterton Global Value L.P. (30%). Mineral Ridge is a conventional open pit mining and heap leach operation. The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages. Scorpio Gold also holds a 100% interest in the advanced exploration-stage Goldwedge property in Manhattan, Nevada, with a fully permitted underground mine and 400 ton per day mill facility. The Goldwedge mill facility has been placed on a care and maintenance basis for the near-term and can be restarted immediately when needed.

Scorpio Gold’s President & CEO, Peter J. Hawley, PGeo,, is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the content of this release.

ON BEHALF OF THE BOARD
SCORPIO GOLD CORPORATION

Peter J. Hawley,
President & CEO

For further information contact:
Peter J. Hawley, CEO
Tel: +1 819 825 7618
Email: phawley@scorpiogold.com

Investor Relations:
Jim Macdonald, Torrey Hills Capital
Tel: (858) 456-7300
Email: jm@sdthc.com

Website: www.scorpiogold.com

Neometals {ASX: MTL} and Mineral Resources {ASX: MRL}  have issued an update concerning their MOU with their potential partner, Jiangxi Ganfeng Lithium Co. Ltd., of China.

This follows on from their previous announcements, and confirms all is on track.

Comment

All seems nicely on tracks here, and it’s nice to see regular updates being issued to inform shareholders, a rarity in the market.

The full news release is below, relevant sections are highlighted for easy reading.

News Release

Neometals Ltd {ASX: MTL} and Mineral Resources Limited {ASX: MRL} refer to their previous announcements regarding the binding Memorandum of Understanding entered into by their jointly owned subsidiary, Reed Industrial Minerals Pty Ltd, with Jiangxi Ganfeng Lithium Co., Ltd.

The parties are continuing to progress the formal agreements to document and give full effect to the terms agreed in the MOU.

The parties are now working towards execution of the formal agreements by 19th September 2015.

Ganfeng has called a meeting of its shareholders to seek approval of the transaction, as contemplated by the MOU. The meeting is scheduled for Monday, 21 September 2015.

Following execution of the formal  agreements, Ganfeng will also seek approval of the transaction from the Jiangxi Provincial Government, which is expected to take approximately one week.

Subject to execution of the formal agreements and the above conditions, financial close of the transaction is expected to occur in early October 2015.

Terrace Energy {TSX.V: TZR} have seen Canaccord Genuity lower their target price for the stock.

However, Canaccord maintain their buy rating for Terrace, and have a new target price of

Canaccord Genuity Lowers Terrace Energy Corp Price Target to C$0.75.

Terrace Energy Corp {TSX.V: TZR}

Research analysts at Canaccord Genuity reduced their price objective on shares of Terrace Energy Corp (CVE:TZR) from C$0.85 to C$0.75 in a research note issued on Friday. The brokerage currently has a “buy” rating on the stock.

Canaccord Genuity’s price target suggests a potential upside of 87.50% from the stock’s previous close.

Terrace Energy Corp. is a Canada-based company, which is engaged in the business of acquiring, exploring and developing onshore oil and gas properties in the United States. The Company uses multi-well pad drilling and unconventional frac designs to develop conventional reservoirs.

The Company’s projects include Olmos Tight Sandstone development project, Maverick County project and Big Wells project. The Company’s Olmos Tight Sandstone Development project consists of eight wells. The Company’s Maverick County project consists of approximately 147,000 gross mineral acres, and is in exploration with Eagle Ford Shale producers, and the Cutlass Eagle Ford development project.

The Company’s subsidiaries include Terrace US Holdings LLC, Terrace Operating, LLC, Terrace Cutlass, LLC, Terrace STS, LLC, TEC Operating, LLC, Terrace BWP, LLC, Terrace Investment Holdings Inc. and TEC Olmos, LLC.

Nouveau Monde {TSX.V: NOU} has released the first drill results from their 2015 drill program at the Matawinie graphite property.

The company are progressing towards a PEA in early 2016.

GATINEAU, QUEBEC SEPTEMBER 10th, 2015 – Nouveau Monde {TSX.V: NOU} is pleased to report its first drilling and trenching assay results for its  ongoing 2015 program on the Matawinie graphite property which is located in the St-Michel-des-Saints area, some 130 km north of Montreal, Québec, Canada.

An extensive trenching and 9000 meters drilling program was initiated on the property’s Tony claim block in late June following repeated discoveries of high grade graphite showings  coincident with multi-kilometric conductive anomalies reported earlier this summer (see press releases dated May 28 and July 9, 2015). The objective of the work program is to define the most promising graphite resource  among the different mineralised zones on the project before year end in order to come up with a preliminary economic assessment during the first half of 2016.
Trenching-channel sampling

A total of five trenches ranging in length from 62 to 198 m were excavated and sampled. Laboratory results are pending, except for trench TO-15-TR-5 dug on the South-West Zone adjacent to drill section S-1500 for which complete assays have been received. Channel samples from the program each measured approximately 2 m in length, 4 cm in width, and 10 cm in height. Although the best individual channel sample result  from this trench is 7.46 % graphitic carbon (“Cg”) over 2 m, a total of 20 samples returned over 5% Cg. The northern contact of the mineralised horizon was intersected, but it remains open to the south where thick overburden (> 3 m) precluded excavation.

The samples were collected in excavated trenches using a portable gas-powered rock saw. The trenches were oriented approximately  perpendicular to the gneissossity whose dip varies from 300 to 900 (vertical). Trench locations are seen on the property map, while assay results are available below (Table 1) and on drill section S-1500. Results from trenches TO-15-TR-06 through TO-15-TR-09 will be reported upon receipt.
Drilling

To date, 29 core drill holes ranging in length from 33 to 183 m were drilled for a total of 3,788 m. The operation generated more than 1,400 samples. This initial drilling program was concentrated in the South-West Zone of the Tony block where 22 of the holes (totaling 2,615 m) were drilled. For this reason, only the work performed in this zone will be discussed further at this time. Although results are pending for 14 of the holes drilled on the zone, some values already stand out: Hole TO-15-10 returned the highest grade, 4.78% Cg over 43.9 m (42.4 m true width), Hole TO-15-07 yielded the highest grade intersection, 4.92% Cg over 27.8 m (27.7 m true width) and Hole TO-15-12 showed the longest intersection, 3.36% Cg over 61.8 m (61.7 m true width).

The location of the drill holes can be seen on the South-West work location map above, while the results received to date are presented in Table 2. As seen on the four sections presented above, from south to north, the drill holes intercepted a number of distinct layers: a first graphitic horizon (S1) about 30 m thick, followed by a mostly barren interval between 25 and 63 m thick, and finally, a second graphitic horizon (S2) around 50 m thick. These horizons dip from 45° to 55° south. Regarding the South-West Zone, drilling indicates that Zones S1 and S2 merge and narrow to the west between sections S-1200 and S-1400, while PhiSpy ground geophysics indicates that Horizons S1 and S2 disappear to the east between sections S-1900 and S-2000. In this context, we believe the geophysical methodology to be very reliable as it has not only been instrumental in discovering the mineralization, but also strongly supports its continuity between the drill sections.
The 2015 drilling program was supervised by Yvan Bussières, P.Eng. (Québec), B.Sc., and the trenching by Antoine Cloutier, P.Geo. (Québec), B.Sc. A strict protocol, including the insertion of duplicate and blank samples within the sample stream was adopted as part of a quality assurance and quality control (QA/QC) program. Graphite standards were also included within the borehole sampling protocol. Duplicate, blank and graphite standard sample results returned values within acceptable limits. Verification,  preparation and sample submittal for the drilling were done by Mr. Bussières whereas Mr. Cloutier was responsible for the same for the channel sampling.

All channel samples were thoroughly washed and individually bagged prior to shipping. Mineralized core samples were chosen for analysis either by Mr. Bussières or Mr. Bernard-Olivier Martel, P.Geo. (Québec), B.Sc. The mineralized drill core was split into quarters using a rock saw. The quarter core samples were then individually bagged and sent for analysis, and the remaining core was kept as a reference and for possible metallurgical testing. Samples were analyzed for graphitic carbon (Cg) content by a LECO analyzer (ALS code; C-IR18) at the ALS Minerals laboratory in North Vancouver (BC), Canada. This laboratory is ISO 9001:2008 and ISO 17025 accredited.

Metallurgical testing

Although the graphite ore head grade remains a moderately important parameter, Nouveau Monde recognizes that a dominant criteria in the  evaluation of the various mineralised zones on the Tony block is dependent on its metallurgy and graphite flake size distribution. Thus, numerous 10 kg samples from each zone were recently collected in trenches and on drill core and delivered to two known laboratories. This exercise will provide crucial information in order to assess graphite ore response to basic metallurgical processes namely crushing, grinding and flotation. The quality of the concentrate produced during these initial metallurgical scoping studies in terms of flake size distribution and concentrate purity will be instrumental in determining which mineralized zone (s) will most likely deliver the best economic potential. These results will be announced once received and compiled. The first metallurgical results (see October 22nd 2014) from the western area of the Tony block were considered exceptional and are repeated in the table below.

Table 3: Summary of metallurgical results received from the western area of the Tony block (see October 22nd 2014 for details)

Flake size concentrate % of Weight % Ct1
+32 mesh 5,5 98,4
+48 mesh 24,6 99,3
+65 mesh 21,2 98,4
+80 mesh 9,0 96,9
+100 mesh 7,4 95,8
+150 mesh 9,1 95,4
Total of 76.8% Average of 97.9%.
The technical information in this news release was prepared by Yvan Bussières, P.Eng., drill program supervisor, and Antoine Cloutier, P.Geo., chief geologist for Nouveau Monde, and reviewed by Eric Desaulniers, MSc, P.Geo., President and CEO of Nouveau Monde. All three are qualified persons under National Instrument 43-101.
For further information, please contact:

Eric Desaulniers, M.Sc., P.Geo.

President and Chief Executive Officer of Nouveau Monde

+1 819 923 0333

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) has in any way passed upon the merits of the proposed transaction or approved or disapproved the contents of this press release.
Except for historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those anticipated by such statements. Nouveau Monde will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Nouveau Monde.
This communication may be considered an advertisement or solicitation under the laws of some territories, states or countries. Nouveau Monde keeps its clientele and business contacts abreast of recent developments by means of regular news bulletins, reports, specialised articles and events. Click here to unsubscribe from the Nouveau Monde mailing list.

TORONTO, ON, Sep 08, 2015  Carlisle Goldfields Ltd. {TSX.V: CGJ}  announces the appointment of Jamie Porter, CPA, CA to the Board of Directors, subject to TSX approval.

This appointment illustrates the closeness of the links between the JV partners at Lynn Lake.

Mr. Porter is the Chief Financial Officer of Alamos Gold and has over 15 years of progressive experience in the mining industry, having started his career at PricewaterhouseCoopers LLP managing audits of public companies.

In 2003, Mr. Porter joined a Central American-based gold producer and held the roles of Controller and Corporate Secretary. In 2005, Mr. Porter joined Alamos as Controller, was promoted to Vice President of Finance in 2008 and to Chief Financial Officer in 2011. Mr. Porter is also a Director of Canadian Feed the Children, a registered charity in Canada.

Mr. Porter replaces Mr. Chris Richter who resigned his position as director on September 4, 2015.

Carlisle’s President and CEO, Abraham Drost, commented that: “we thank Chris Richter for his service on the Carlisle Board and wish him all the best with his new venture. We welcome Jamie Porter to the Carlisle board and look forward to a productive future with our joint venture partner Alamos Gold.”

About Carlisle Goldifelds

Carlisle Goldfields Limited is a gold exploration and development company on an earn-in and joint venture with Alamos Gold Inc. {TSX.V: AGI} working towards feasibility and development of its Lynn Lake Gold Camp in Lynn Lake, Manitoba, Canada. Carlisle has NI 43-101 compliant mineral resource estimates on five (5) deposits within its Lynn Lake Gold Camp, four of which form the basis for the February, 2014 (www.sedar.com) Preliminary Economic Assessment (“PEA”) technical report (Farley Lake Mine Deposit, MacLellan Mine Deposit, Burnt Timber Mine Deposit, and Linkwood Deposit).

A second PEA technical report filed in April, 2014 focused on an open pit mining and processing model for the past-producing Farley Lake Mine and MacLellan Mine deposits. The latter is the starting point for further feasibility level engineering and development work by the Lynn Lake Joint Venture in the current study with Alamos as Operator.

Carlisle’s objective, together Alamos, its government, municipal and First Nation project stakeholders, is to efficiently advance the Lynn Lake Gold Camp Project through a compliant feasibility study, environmental and mine permitting to set the stage for resumption of gold production in the historical Lynn Lake mining camp, Manitoba.

Further details including mineral resource technical reports are available on SEDAR (www.sedar.com) or carlislegold.com/resource-summary.php

This press release shall not constitute an offer to sell or solicitation of an offer to buy the securities in any jurisdiction. The Company’s shares and other securities have not been and will not be registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent an applicable exemption from the registration requirements.

Except for statements of historical fact contained herein, the information in this press release may constitute “forward-looking information” within the meaning of Canadian securities law. Other than statements of historical fact, all statements are “forward-looking statements”, including the establishment and estimate of resources that involve various known and unknown risks and uncertainties and other factors. There can be no assurance that such statements will prove accurate. Results and future events could differ materially from those anticipated in such statements. Readers of this press release are cautioned not to place undue reliance on these “forward-looking statements”. Except as otherwise required by applicable securities statutes or regulation, Carlisle expressly disclaims any intent or obligation to update publicly forward-looking information, whether as a result of new information, future events or otherwise.

Neither IIROC nor the TSX accepts responsibility for the adequacy or accuracy of this press release.

Carlisle Goldfields Limited
Nicholas Konkin
Director of Investor Communications
+1 416-642-0869 ext. 3
nk@carlislegold.com

Carlisle Goldfields Limited
Abraham Drost
President & CEO
+1 807-252-7800
adrost@carlislegold.com

info@carlislegold.com
www.carlislegold.com
SOURCE: Carlisle Goldfields Limited

Inovio Pharmaceuticals (NASDAQ: INO} have announced the dosing of the first patient with their universal HIV vaccine phase 1 trial.

The vaccine targets multiple cledes (strains) of the HIV virus so as to be universally effective.

Inovio Pharmaceuticals Announces First Patient Dosed With Universal HIV Vaccine

PLYMOUTH MEETING, Pa. – September 8, 2015 – Inovio Pharmaceuticals, {NASDAQ: INO} announced today that the first patient has been dosed in a phase I trial to evaluate safety and tolerability of PENNVAX®-GP, Inovio’s “universal” DNA vaccine for HIV.

This human study is in collaboration with the HIV Vaccine Trials Network (HVTN). The trial will measure immune responses following administration of the vaccine in four groups of healthy subjects receiving the vaccine with and without an immune activator (IL-12) and delivered into muscle or skin using Inovio’s CELLECTRA® delivery technology. This study is conducted by the HVTN and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Development of the PENNVAX-GP vaccine, which targets multiple clades of HIV—providing global coverage—has been funded through a $25 million NIAID contract awarded to Inovio and its collaborators. Earlier this year, Inovio and its collaborators were awarded a five-year $16 million Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from NIAID. This new five-year program grant was awarded based on a peer-reviewed meritorious proposal by Dr. David Weiner, from the University of Pennsylvania and chair of Inovio’s scientific advisory board, and Inovio.

Dr. J. Joseph Kim, President and CEO, said, “This latest HIV vaccine trial will allow us to test our universal HIV vaccine, with the potential to provide protection against viruses from all major global clades. This is a major step forward in extending our clinical experience with the PENNVAX platform and the innovation developed from our previous PENNVAX human trials. We are confident that the results of this trial will advance our previous findings that demonstrated best-in-class cellular immune responses. Inovio looks forward to continuing our long-standing and fruitful collaborations with both NIAID and HVTN.”

Results from the previous PENNVAX phase I trial, HVTN 080, were published in Journal of Infectious Diseases in 2013 and showed that 89% (24/27) of subjects developed a robust CD4 or CD8 response. In addition, immune response rates remained strong and persistent six months after vaccination. Achieving a robust CD8 T-cell response in a significant number of patients had been a previous barrier for HIV researchers.

Importantly, PENNVAX was able to generate CD8 T-cell responses with significant magnitude as measured by the HVTN core laboratory at the Fred Hutchinson Cancer Center, whose assays have been standardized to evaluate several different vaccine delivery technologies. Notably, CD4 and CD8 T-cells are both important in cellular immunity, however, CD8 T-cells are considered especially integral to fighting cancers and chronic infectious diseases. The PENNVAX-GP product was developed as a universal HIV vaccine to expand and improve the coverage of the earlier version of PENNVAX against multiple divergent virus strains and clades across the globe.

About HIV Infection

Nearly 36 million people have died from HIV-related causes and 35 million are living with HIV. HIV is a retrovirus that causes acquired immunodeficiency syndrome (AIDS), a condition in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. HIV is classified into clades, sub-types within which the virus has genetic similarities. The most prevalent clades are B (found mainly in North America and Europe), A and D (found mainly in Africa), and C (found mainly in Africa and Asia).

HIV clade C accounts for 48% of worldwide and 51% of African-HIV type 1 cases. It is the most rapidly spreading subtype of HIV. Although a highly active antiretroviral therapy regimen has dramatically transformed the treatment of the disease in developed countries, effective HIV vaccines are needed to stop the spread of disease and reduce the need for antiretroviral treatments, which can have harsh side effects and lose their efficacy over time.

About Inovio’s PENNVAX® HIV Vaccines and Immunotherapies

Inovio completed initial clinical studies of its HIV immunotherapy PENNVAX-B, targeting clade B viruses, to achieve proof of principle in generating potent immune responses using its SynCon® immunotherapy technology. In two published phase I studies, PENNVAX-B immunization generated high levels of activated, antigen-specific CD8+ killer T cells with proper functional characteristics. This ability uniquely positions PENNVAX as an important product candidate for both preventing and treating HIV infections.

Using a $25 million contract from the NIH, Inovio designed its universal, multi-clade, multi-antigen PENNVAX GP immunotherapy targeting the env, gag and pol antigens to provide coverage against all major HIV-1 clades. PENNVAX-GP is Inovio’s lead preventive and therapeutic immunotherapy for HIV.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that is generating T cells, in vivo, in high quantity that are fully functional whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit www.inovio.com.

CONTACTS:
Investors: Bernie Hertel,

Inovio Pharmaceuticals.

+1 858 410 3101

Email bhertel@inovio.com

The USA and Canada were closed today – So no news updates nor any precious metals market.

All countries are back trading tomorrow, Tuesday 8th September 2015.

Despite the market been in the depths of despair, a bidding war Between Batero Mining {TSX.V: BAT}, and Red Eagle Mining for control of CB gold has hotted up, with an improved offer from Batero pipping Red Eagle’s latest bid.

Let’s see if any counter bids emerge in due course!

Batero boosts offer for CB Gold to six cents a share

2015-09-05 02:20 ET – News Release

Mr. Michael Mills reports

BATERO SIGNIFICANTLY RAISES OFFER TO ACQUIRE CB GOLD

Batero Gold Corp. has significantly increased its previous offer to acquire all of the outstanding common shares of CB Gold Inc. to six cents per CB Gold common share. Batero and CB Gold have entered into an amended support agreement to reflect the amended Batero offer. CB Gold’s board of directors unanimously supports the amended Batero offer and unanimously recommends that CB Gold shareholders tender to the amended Batero offer.

The amended Batero offer represents a substantial 23-per-cent premium to the hostile Red Eagle Mining Corp. offer based on Sept. 4, 2015, closing prices. The value of today’s amended Batero offer represents a 71-per-cent premium to the closing price of CB Gold common shares on July 23, 2015, the day before the announcement of Batero’s initial offer. In connection with the amended Batero offer, Batero will file and mail a notice of variation and extension to CB Gold shareholders.

CB Gold shareholders who tender to the amended Batero offer will be entitled to receive, at their option, for each CB Gold common share either six cents in cash or 0.80 of a Batero share, in each case pro rata. The maximum amount of cash payable by Batero under the amended Batero offer will be equal to one-half (approximately $5.4-million) of the total consideration. The maximum number of shares issuable by Batero under the amended Batero offer will be approximately 72.3 million (based on the number of CB Gold common shares outstanding on Sept. 4, 2015).

The amended support agreement increases the definition of consideration to reflect the amended Batero offer, allows Batero to decrease or waive the minimum tender condition without consent from CB Gold in certain circumstances, and amends the termination fee to $420,000 (U.S.).

Batero is also pleased to announce that it has entered into a lock-up agreement with Silvercorp Metals Inc., pursuant to which Silvercorp has agreed to tender to the amended Batero offer all of the CB Gold common shares held by it. Copies of such lock-up agreement and the amended support agreement will be filed with securities regulators and will be available on SEDAR. The lock-up of Silvercorp, a sophisticated party, is a signal of strong support for the amended Batero offer.

The amended Batero offer provides CB Gold shareholders far-superior value and the choice of the certainty of cash or significant upside.

Financial benefits of the Batero offer

The Batero offer provides a higher premium and the choice of value certainty or more upside versus the Red Eagle offer. Based on Sept. 4, 2015, closing prices, the implied value of Batero’s offer, six cents per CB Gold common share, is more than 23 per cent higher than the value of the Red Eagle offer of 4.86 cents. Batero has increased the premium paid to CB Gold shareholders from 44 per cent to 71 per cent, based on the closing prices on July 23, 2015, the day before the announcement of Batero’s initial offer.

Batero is offering six cents per CB Gold common share in cash (pro rata such that a maximum of 50 per cent of its total consideration is in cash) or offering 0.80 of a Batero share for each CB Gold share for those CB Gold shareholders who want to participate in the upside of Batero’s projects.

Batero has the technical and financial capacity to unlock value for its shareholders going forward with its objectives of advancing the Vetas and Quinchia projects. CB Gold shareholders electing shares will gain exposure to Batero’s preliminary-economic-assessment-stage Batero-Quinchia project.

Red Eagle is currently focused on construction of its own project, which could be subject to delays, and cash flow is at risk of being diverted to service the Red Eagle debt.

The Batero offer is supported by CB Gold’s board of directors. The Batero offer is the only bid which has received unanimous support from CB Gold’s board of directors. Including the Silvercorp shares, holders of nearly 30 per cent of CB Gold common shares have already tendered to the initial Batero offer even though there is time remaining until expiry.

Despite having its bid outstanding for more than 60 days, Red Eagle has not managed to get the majority of CB Gold shareholders to support its inferior proposal.

CB Gold shareholders will benefit from the technical expertise of Consorcio Minero Horizonte on the back of CMH’s alliance with Batero.

CMH has been in operation for over 35 years. CMH has the know-how to help Batero advance the Vetas project through permitting and development. CMH produces more than 250,000 ounces of gold per year in Peru and has mined close to three million ounces over the last two decades. CMH employs more than 3,500 people. Batero and CB Gold shareholders will be able to draw on CMH’s deep underground mining expertise. Throughout its history, CMH has developed more than 100 kilometres of underground headings and sublevels at depths in excess of 700 metres.

Red Eagle has stated that it is focused on developing the Santa Rosa deposit, and any attention to Vetas will be subordinate to the main project. To date, Red Eagle has not produced an ounce of gold and has not operated a gold mine, whether underground or open pit.

CB Gold shareholders will benefit from the financial resources of Batero and strong backing of its partner CMH. Batero has already demonstrated its financial capacity by providing CB Gold shareholders with a cash component and by providing CB Gold with a $575,000 private placement to keep the company solvent. As of May 31, 2015, adjusting for the private placement, Batero had a cash balance of $11.5-million.

Batero has the backing and support of CMH, which has been a strong technical and financial supporter of Batero since 2012. Given the turbulence in the gold markets, all of Batero’s shareholders benefit from CMH’s position in the company. As the company unlocks value, all of Batero’s shareholders will be completely aligned to benefit.

Meanwhile, Red Eagle has refused to support CB Gold. Red Eagle is coping with a debt burden and has limited resources to divert toward the Vetas project. Red Eagle’s outstanding debt includes a $60-million (U.S.) credit facility to build its own Santa Rosa project. The facility is greater than the unlevered net present value of the Santa Rosa project of approximately $43-million (U.S.), according to its own feasibility study (at a discount rate of 8 per cent and a gold price of $1,100 (U.S.) per ounce).

Red Eagle’s shares are concentrated in the hands of three mine finance groups and a mining contractor.

These shareholders together control more than 60 per cent of the shares outstanding in Red Eagle. These parties have business objectives which may not align with the interests of all shareholders. They have taken advantage of this control position to extract dilutive royalties and production payments and provide excessive leverage.

How to tender CB Gold common shares to the Batero offer

All questions regarding the Batero offer and how to tender CB Gold common shares to the Batero offer should be directed to Kingsdale Shareholder Services, the information agent and depository, at 1-866-581-0506 (North American toll-free) or 1-416-867-2272 (collect calls) or by e-mail at ontactus@kingsdaleshareholder.com.

Shareholders should also contact Kingsdale Shareholder Services for assistance if they have tendered their shares to the Red Eagle offer to withdraw them immediately, and in any event prior to the Sept. 14, 2015, expiry date of the hostile Red Eagle offer.

We seek Safe Harbor.

Condor Gold {AIM: CNR} surprised the market by announcing that management have initiated a strategic review of operations, and initiated a commencement of offer period for either the company or any of the component parts.

Condor are a prudent, well run company and had been expected to advance the project to production themselves.

Comment

This news comes as a bit of a surprise, effectively Condor feel they cannot raise the finance to bring the project into production, at the current price of gold.

Whilst this in itself is not a surprise, given the state of the markets , Condor were one of the better run junior companies, and I personally expected them to bring La India into production themselves. Mark Child is a serious and competent person, and in a better market he would have achieved production himself. This announcement highlights the dearth of investment money currently available to junior miners, and the lack of confidence in the price of gold going forwards.

This situation needs to happen to at least two thirds of the TSX Venture Exchange, where those companies have absolutely no hope of ever raising the required finance to bring their projects into production, and are, instead, focusing on paying management salaries to keep a lifestyle vehicle going on life support for their own benefit.

News release

Condor Gold PLC Strategic review and commencement of offer period

TIDMCNR

RNS Number : 1978Y

Condor Gold PLC

04 September 2015

FOR IMMEDIATE RELEASE 4 September 2015
Condor Gold Plc

(“Condor” or the “Company”)

Strategic review and commencement of an offer period

The Board of Condor announces that it has initiated a formal strategic review of the Company’s business and assets with a view to maximising the best value for Shareholders at this time. Accordingly, the Company has appointed Cormark Securities Inc. (“Cormark”) to act as financial advisor assisting with exploring value creating alternatives for the Company.

Condor is a gold exploration company and over the last 5 years has successfully proved an independent mineral resource at its flagship La India Project in Nicaragua of 18.1M tonnes at 4.0g/t containing 2.32M oz gold, which includes an open pit mineral reserve of 6.9M tonnes at 3.0g/t gold containing 675,000 oz gold. An NI 43-101 technical report detailing a Pre-Feasibility Study (“PFS”) and two Preliminary Economic Assessments (“PEAs”) were posted on Condor’s website on 21(st) December 2014.

The Board has conducted an internal review of strategic options going forward against the backdrop of a gold price that has corrected approximately 40% from its all time high 3 years ago and the lack of appetite for equity financing in the junior gold exploration sector. The Board has concluded that the equity required for the construction of a mine at La India Project, given the upfront capital cost of between US$ 110M and US$ 169M estimated in the PFS and PEA’s would prove significantly dilutive to existing shareholders.

Furthermore, there is no guarantee that either equity or debt financing for the construction of the mine and associated infrastructure can be secured on satisfactory terms. The Board’s view is that the completion of a Definitive Feasibility Study (“DFS”), while adding value to the Project, would be unlikely to be fully recognised in the share price and in any case, in the event that the strategic review results in an eventual sale of the Company’s business or assets or of the Company itself, the DFS would be substantially reviewed by any acquirer. Condor will continue with its strategy of de-risking the La India Project by applying for an EIA Permit and securing the rural land, while continuing to show the upside of the Project through a soil survey programme, a detailed structural geology study and completing an enterprise optimisation study on the reserves and resources in the PFS and PEAs.

One of the options being considered would be a possible offer for the Company. Another option is for a joint venture or sale of one or more of the Company’s assets, including the independent mineral resource estimate in El Salvador of 13.1M tonnes at 2.6g/t containing 1.1M oz gold equivalent.

Takeover Code

Any discussions in relation to a merger with a third party or a sale of the Company will take place within the context of a “formal sale process” as defined in The City Code on Takeovers and Mergers (the “Code”) in order to enable conversations with parties interested in making such a proposal to take place on a confidential basis.

The Takeover Panel has granted a dispensation from the requirements of Rules 2.4(a), 2.4(b) and 2.6(a) of the Code such that any interested party participating in the formal sale process will not be required to be publicly identified as a result of this announcement (subject to note 3 to Rule 2.2 of the Code) and will not be subject to the 28 day deadline referred to in Rule 2.6(a), for so long as it is participating in the formal sale process. Interested parties should note Rule 21.2 of the Code, which will prohibit any form of inducement fee or other offer-related arrangement, and that the Company, although it may do so in the future, has not at this stage requested any dispensation from this prohibition under Note 2 of Rule 21.2.

This announcement is not an announcement of a firm intention to make an offer under Rule 2.7 of the Code and there can be no certainty that an offer will be made, nor as to the terms on which any offer will be made.

Following this announcement, the Company is now considered to be in an “offer period” as defined in the Code, and the dealing disclosure requirements listed below will apply.

Beaumont Cornish Limited (“Beaumont Cornish”), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Condor and for no one else in connection with the subject matter of this announcement and will not be responsible to anyone other than Condor for providing the protections afforded to its clients or for providing advice in connection with the subject matter of this announcement.

The following information is provided in accordance with Rule 2.10 of the City Code on Takeovers and Mergers (the “Code”).

Relevant Securities in Issue

The Company confirms that it has 45,807,316 Ordinary Shares of 20 pence each in issue at the close of business on 3 September 2015 and the Ordinary Shares in the Company are admitted to trading on AIM under the UK ISIN code GB00B8225591.

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.

An Opening Position Disclosure must contain details of the person’s interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person’s interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel’s website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. You should contact the Panel’s Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

In accordance with Rule 26.1 of the Code, a copy of this announcement will be published, subject to certain restrictions relating to persons in any restricted jurisdiction at www.condorgold.com

Enquiries:
Condor Gold plc
Mark Child, Executive Chairman and CEO

Tel:  0207 408 1067

Beaumont Cornish Limited
James Biddle/ Roland Cornish

Tel: 0207 628 3396

Cormark Securities Inc.

Tel: +1 416-943 6411
AX

Range Energy {CSE: RGO} have confirmed that they and their partners are about to begin development drilling at Khalakan.

Target production is around 10,000 BOPD. This is the first news release for several years and in a better market would result in a re-rating for the stock.

Range Energy’s Gas Plus to begin drilling at Shewashan

SHEWASHAN FIELD DEVELOPMENT PLAN APPROVED, TARGETS 10,000 BOPD IN 2016

2015-09-01 19:14 ET – News Release

Mr. Toufic Chahine reports

On Sept. 1, 2015, Gas Plus Khalakan, the sole contractor of the Khalakan block in the Kurdistan region of Iraq, made public that it is about to  commence development drilling to support phase 1 of the approved Shewashan field development plan and the installation of an early production facility with target production of 10,000 barrels of oil per day in 2016.

The article includes additional important information regarding the performance of the Shewashan-1 well, proved plus probable oil reserves and results from a 180-day production period.

The company(Range Energy)  is a 24.95-per-cent indirect shareholder of GPK through its ownership of 49.9 per cent of the shares of New Age Alzarooni 2 Ltd. NAAZ2 owns 50 per cent of the shares of GPK.

Please note the company’s earlier press release on Sept. 1, 2015, “Range Energy reaches agreement to temporarily suspend litigation regarding information disclosure.”

We seek Safe Harbor.